Checking how well an index predicts blood cancer care
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at how well a measurement called the OHI Index works for people with blood cancers. It may help doctors better assess risk or needs, but it mainly focuses on validating the tool rather than testing a new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have a blood cancer (a hematologic malignancy)
- You have not had chemotherapy or similar treatments in the last month
- You should be able to join as a patient being followed over time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study is a disease registry that collects medical information from children who have hemophagocytic lymphohistiocytosis (HLH) or are suspected to have it. It helps doctors better understand HLH and how it affects patients over time.
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
Hear when a new HLH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.